UNSPSC 51391726: Orciprenaline or metaproterenol

This classification denotes a bronchodilator with the molecular formula C11H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53QOG569E0, chemically known as 3,5-dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol but generally known as metaproterenol, which bears US NIH Compound Identifier 4086. European Medicines Agency schedules Metaproterenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09457MIG. The term METAPROTERENOL is an International Non-Proprietary Name.

World Health Organization schedules metaproterenol in its Anatomical Therapeutic Chemical (ATC) Classification. Orciprenaline or metaproterenol bears US NLM identifiers UMLS ID C0029193 and NCI Concept Code C61834. SMILES: CC(C)NCC(C1=CC(=CC(=C1)O)O)O.

UNSPSC 51391726 Orciprenaline or metaproterenol is a Commodity code that captures pharmaceutical products, though recent state and local procurement activity under this code shows minimal alignment with the nominal scope. The single recent opportunity tagged to this code involves naloxone and drug deactivation systems rather than orciprenaline or metaproterenol, suggesting either a tagging misclassification in the procurement record or that this code is rarely used for its intended pharmaceutical application in state and local contracting. State and local buyers appear to access these products through other channels or code designations, leaving this Commodity with little visible activity in the recent market.

Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The bid deadline was July 26, 2023, with vendors required to submit electronic bids through the county's e-Procurement Portal, include all shipping and delivery costs, maintain workers' compensation and commercial general liability insurance, and comply with E-Verify and drug-free workplace requirements. The contract included a two-year initial term with a one-year renewal option and a three-month probationary period. This represents the only recent opportunity visible under the code; geographic concentration in Florida and the absence of additional state or local solicitations suggest limited current procurement activity or systematic misclassification of pharmaceutical purchases under this code designation.